The New England journal of medicine
-
Editorial Comment
A Bacterial IgG-Degrading Enzyme to Unhinge Antibodies.
-
Randomized Controlled Trial Multicenter Study
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.
Patients with acute myeloid leukemia (AML) and a FLT3 mutation have poor outcomes. We conducted a phase 3 trial to determine whether the addition of midostaurin - an oral multitargeted kinase inhibitor that is active in patients with a FLT3 mutation - to standard chemotherapy would prolong overall survival in this population. ⋯ The addition of the multitargeted kinase inhibitor midostaurin to standard chemotherapy significantly prolonged overall and event-free survival among patients with AML and a FLT3 mutation. (Funded by the National Cancer Institute and Novartis; ClinicalTrials.gov number, NCT00651261 .).